Department of Pediatrics, Stanford University, Stanford, CA, USA.
Department of Genetics, Stanford University, Stanford, CA, USA.
EMBO Mol Med. 2021 Jan 11;13(1):e13122. doi: 10.15252/emmm.202013122. Epub 2020 Dec 9.
Metastasis is a major cause of morbidity and mortality in cancer patients. However, the molecular and cellular mechanisms underlying the ability of cancer cells to metastasize remain relatively poorly understood. Among all solid tumors, small cell lung cancer (SCLC) has remarkable metastatic proclivity, with a majority of patients diagnosed with metastatic disease. Our understanding of SCLC metastasis has been hampered for many years by the paucity of material from primary tumors and metastases, as well as the lack of faithful pre-clinical models. Here, we review recent advances that are helping circumvent these limitations. These advances include methods that employ circulating tumor cells from the blood of SCLC patients and the development of diverse genetically engineered mouse models of metastatic SCLC. New insights into the cellular mechanisms of SCLC metastasis include observations of cell fate changes associated with increased metastatic ability. Ongoing studies on cell migration and organ tropism promise to expand our understanding of SCLC metastasis. Ultimately, a better molecular understanding of metastatic phenotypes may be translated into new therapeutic options to limit metastatic spread and treat metastatic SCLC.
转移是癌症患者发病率和死亡率的主要原因。然而,癌症细胞转移能力的分子和细胞机制仍知之甚少。在所有实体肿瘤中,小细胞肺癌(SCLC)具有显著的转移倾向,大多数患者被诊断为转移性疾病。多年来,我们对 SCLC 转移的理解受到原发性肿瘤和转移灶中缺乏物质以及缺乏忠实的临床前模型的阻碍。在这里,我们回顾了帮助克服这些限制的最新进展。这些进展包括使用 SCLC 患者血液中的循环肿瘤细胞的方法,以及开发多种转移性 SCLC 的基因工程小鼠模型。对 SCLC 转移细胞机制的新见解包括观察到与增加转移能力相关的细胞命运变化。关于细胞迁移和器官趋向性的正在进行的研究有望扩大我们对 SCLC 转移的理解。最终,对转移表型的更好分子理解可能会转化为新的治疗选择,以限制转移扩散并治疗转移性 SCLC。